DERMATOP E EMOLLIENT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DERMATOP E EMOLLIENT (DERMATOP E EMOLLIENT).
Prednicarbate is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins, leukotrienes, and other inflammatory mediators.
| Metabolism | Prednicarbate is metabolized primarily in the skin and systemically via esterases and cytochrome P450 enzymes, with prednisolone as a major metabolite. |
| Excretion | Predominantly hepatic metabolism; renal excretion of metabolites <5% unchanged; biliary/fecal excretion minimal. |
| Half-life | Terminal elimination half-life: 18-36 hours. Clinically, once-daily dosing maintains therapeutic effect. |
| Protein binding | >99% bound to plasma proteins (albumin and corticosteroid-binding globulin). |
| Volume of Distribution | Approximately 1.4 L/kg; indicates extensive tissue distribution, not restricted to plasma. |
| Bioavailability | Topical: 1-3% systemic absorption through intact skin; higher with occlusive dressing or damaged skin. |
| Onset of Action | Topical: 1-2 weeks for noticeable improvement in dermatologic conditions; maximal effect by 4 weeks. |
| Duration of Action | Duration: 24 hours with once-daily application; sustained effect with continued use. |
| Molecular Weight | 504.58 |
Apply a thin layer topically to affected areas twice daily. Maximum 3-week course.
| Dosage form | CREAM |
| Renal impairment | No adjustment required; systemic absorption is minimal. |
| Liver impairment | No adjustment required; local application with minimal systemic exposure. |
| Pediatric use | Not recommended for use in children under 3 months. For children 3 months to 18 years: apply a thin layer topically to affected areas once daily for up to 3 weeks. |
| Geriatric use | No specific adjustment required; use with caution due to increased potential for skin atrophy, telangiectasia, and other local adverse effects. |
| 1st trimester | Topical corticosteroids are generally avoided in the first trimester unless benefit outweighs risk. Limited data; prednicarbate is a weak to moderate potency corticosteroid, systemic absorption is low with intact skin. |
| 2nd trimester | Use with caution; avoid prolonged use on large areas. Low systemic absorption suggests minimal risk. |
| 3rd trimester | Use with caution; avoid prolonged use on large areas. No known teratogenic effects; risk of fetal growth restriction with prolonged high-dose use. |
Clinical note
Comprehensive clinical and safety monograph for DERMATOP E EMOLLIENT (DERMATOP E EMOLLIENT).
| Placental transfer | Topical corticosteroids cross the placenta in small amounts; systemic absorption is low with intact skin. Degree depends on potency, application site, and duration. Prednicarbate is a weak to moderate potency corticosteroid, so transfer is minimal. |
| Breastfeeding | Topical corticosteroids are excreted in breast milk in negligible amounts when used on small areas for short duration. Avoid application to breasts or large areas. Monitor infant for adrenal suppression if prolonged high-dose use. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to prednicarbate or any component of the formulationUntreated bacterial, fungal, or viral skin infections
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Local adverse reactions include skin atrophy, striae, telangiectasias, and secondary infections, Use with occlusive dressings increases systemic absorption, Avoid prolonged use on face, intertriginous areas, or in children |
| Food/Dietary | No clinically relevant food interactions. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 - Safer |
| Teratogenic Risk | Topical corticosteroids are considered low risk for teratogenicity when used at recommended doses. Systemic absorption is minimal with DERMATOP E EMOLLIENT (prednicarbate 0.1%). No adequate and well-controlled studies in pregnant women. Animal studies have shown corticosteroids to be teratogenic after systemic administration. In first trimester, avoid high potency or large areas. In second and third trimesters, use only if clearly needed, avoiding prolonged use on extensive areas or occluded skin. |
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. If used on large areas or under occlusion, monitor for maternal skin atrophy, striae, or systemic effects. In fetus, no specific monitoring indicated. |
| Fertility Effects | No studies on fertility effects in humans. Animal studies with systemic corticosteroids have shown impairment of fertility. Topical use at recommended doses is unlikely to affect fertility. |
| DERMATOP E EMOLLIENT (prednicarbate) is a medium-potency topical corticosteroid. Use short-term for eczema and dermatitis. Avoid prolonged use on intertriginous areas due to increased absorption. Not for ophthalmic or oral use. Occlusion increases potency. |
| Patient Advice | Apply a thin layer to affected skin only, not to normal skin. · Do not use for longer than 2 weeks unless directed by your doctor. · Avoid contact with eyes, mouth, and open wounds. · Do not cover treated area with bandages or dressings unless instructed. |